2247 GMT - Monash IVF's share-price fall following this week's profit warning leaves the company more vulnerable to a bid. Jefferies says reasons for Monash IVF lowering FY 2025 profit guidance to some A$27.5 million likely include the discretionary nature of IVF treatment as well as Monash IVF's exposure to Victoria, a state that is facing economic challenges. "We do not expect a sudden turnaround in IVF volumes but highlight there may be corporate interest in IVF if an acquirer is willing to take a longer-term view given favorable industry dynamics," analyst David Stanton says. Monash IVF's shares are down around 47% over the past 12 months. (david.winning@wsj.com; @dwinningWSJ)
(END) Dow Jones Newswires
May 21, 2025 18:47 ET (22:47 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.